COVID 19 ANTOBODIES IN PREGNANT WOMEN AND THEIR CONNECTION TO BETA CELL FUNCTION IN THE FETUS

Sponsor
Maaynei Hayesha Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04860908
Collaborator
(none)
100
1
14.2
7.1

Study Details

Study Description

Brief Summary

The aim of this study is to check for the presence of COVID 19 antibodies [Covid-19, GAD-65, IA-2, ICA] in the blood of laboring women who have been exposed to either the virus itself or to the vaccine during pregnancy . The same test will be done on cord blood. Then the types of antibodies will be compared, between maternal and neonatal blood. The blood will be taken along with routine blood tests without additional punctures of Mother or Baby.

Condition or Disease Intervention/Treatment Phase
  • Other: no intervention, observation only

Detailed Description

T1D is caused by an autoimmune reaction to proteins that cause the destruction of the pancreatic beta cells. The incidence of childhood Type 1 diabetes (T1D) is continuously increasing, caused by environmental factors, mainly viruses (1).

The most implicated viruses are coxsackie B4 (2) and rotaviruses (3,4). In the past mumps and rubella viruses gave been found to cause early childhood T1D and the introduction of mumps and rubella vaccination have stopped this process (5).

Recently we (6) and others (7-9) have shown that Rotavirus vaccination to infants attenuates the incidence of T1D in children aged 0-5 (in press). Covid-19 has not yet been investigated.

Aim of study To determine whether anti-Covid-19 antibodies generated by infection and/or vaccination of pregnant mothers, pass the placenta and affect the fetal beta-cells, by damaging or protecting these insulin producing cells.

Subjects 100 pregnant women with Covid-19 infection or vaccination who are followed and delivered at the Mayanei HaYeshua Medical Center will be enrolled in the study.

Method

Blood from the pregnant mothers will be taken at delivery (and before if possible) as well as from the cordblood. The following βcell specific antibodies will be tested in the laboratory of the Schneider Children's Hospital:

Covid-19, GAD-65, IA-2, ICA. (ml blood from the mother and 1ml cordblood) The bloods will have to be centrifuged within 20-30 minutes and the sera kept at -20ºC until delivery.

Background Whether the Covid-19 epidemic affects childhood T1D is controversial (10). Flannery et al (11) and Atyeo et al., reported that SARS-Cov-2 infected mothers transmit SARS-Cov-2 antibodies via the placenta to the fetus Fernandez reported protective Covid-19 antibodies in breast milk of infected mothers (13). Kamrath et al from Germany (14) and Rabbone et al from Italy (15) reported a high prevalence of DKA in children diagnosed with T1D during the recent pandemic.

As the Covid-19 virus with its various mutations is known to affect several organs and cells in the human body it is of great interest to know whether it affects also the pancreatic βcells of the fetus.

Hypothesis We assume that unvaccinated mothers transfer the virus antibodies to the fetus, and which may be the first damage to the βcells endangering future development of future type 1 childhood diabetes. Transfer of Covid protecting antibodies may beneficially affect the infant at risk.

Discussion and importance of the study To the best of our knowledge, no such study has been performed.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
DOES COVID-19 INFECTION AND/OR VACCINATION OF PREGNANT WOMEN AFFECT THE PANCREATIC BETA CELLS OF THE FETUS BECOMING A TRIGGER FOR FUTURE DEVELOPMENT OF CHILDHOOD TYPE 1 DIABETES
Actual Study Start Date :
Apr 26, 2021
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
covid exposed

women who were exposed to covid 19 during pregnancy

Other: no intervention, observation only
no intervention, observation only

covid vaccinated

women who were vaccinated to covid 19 during pregnancy

Other: no intervention, observation only
no intervention, observation only

Outcome Measures

Primary Outcome Measures

  1. Presence of anti COVID 19 antibodies in maternal and cord blood [ONE YEAR]

    Covid-19, GAD-65, IA-2, ICA

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 48 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • exposure to the COVID 19 virus or vaccine during pregnancy
Exclusion Criteria:
  • Age under 18 or over 48 IUFD

Contacts and Locations

Locations

Site City State Country Postal Code
1 Maayanei Hayeshua Medical Center Bnei Brak Merkaz Israel

Sponsors and Collaborators

  • Maaynei Hayesha Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mirra Manevich Mazor, OBSTETRICS & GYNECOLOGY RESIDENT, Maaynei Hayesha Medical Center
ClinicalTrials.gov Identifier:
NCT04860908
Other Study ID Numbers:
  • MaayneiHMC
First Posted:
Apr 27, 2021
Last Update Posted:
Apr 27, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mirra Manevich Mazor, OBSTETRICS & GYNECOLOGY RESIDENT, Maaynei Hayesha Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 27, 2021